![logo](/logos/BNOX.webp)
Bionomics Limited
NASDAQ:BNOX
0.59 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Bionomics Limited |
Symbool | BNOX |
Munteenheid | USD |
Prijs | 0.595 |
Beurswaarde | 7,110,820 |
Dividendpercentage | 0% |
52-weken bereik | 0.5 - 6.41 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Spyridon Papapetropoulos M.D., Ph.D. |
Website | https://www.bionomics.com.au |
An error occurred while fetching data.
Over Bionomics Limited
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)